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Turnaround timeBackground: Ventilator-associated pneumonia (VAP) is a frequent hospital-acquired infection in critically
ill children. The increasing incidence of infections by antibiotic-resistant pathogens adds significantly to
the cost of hospital care and to the length of hospital stays. Besides clinical prerequisites for presumptive
diagnosis of VAP, rapid identification of the causative pathogen is essential for appropriate treatment.
Aim of study: To identify the causative bacterial pathogens of VAP by both conventional microbiological
cultures and multiplex reverse transcriptase reaction (m-PCR) methods with assessment of turnaround
time for both diagnostic modalities together with their diagnostic accuracy.
Methods: Patients were diagnosed to have VAP when their Clinical Pulmonary Infection Score (CPIS)
index was more than 6. Endotracheal aspirate was subjected to both microbiological cultures and multi-
plex PCR for bacterial pathogens.
Results: Multiplex-PCR showed better sensitivity and positive predictive value than bacterial culture for
etiological diagnosis of VAP. Acinetobacter and Klebsiella pneumoniae were the most common identified
pathogens. Mean turnaround times were 6 h for multiplex PCR and 72 h for conventional microbiology.
Significant shorter turnaround time was recorded with m PCR compared to microbiological culture.
Conclusion: Multiplex-PCR permits simultaneous detection of several bacterial pathogens in a single
reaction with best turnaround time that permit optimization of emergency diagnosis of VAP and subse-
quently improve early management of selective bacterial pathogens.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Etiologic diagnosis of Ventilator-associated pneumonia is con-Within twelve hours of endotracheal intubation; a biofilm is
formed around the endotracheal tube which contains large
amounts of bacteria that can be disseminated into the lungs by
ventilator-induced breaths. This biofilm may become dislodged
during suctioning, or repositioning of the endotracheal tube [1].
Impaired muco-ciliary clearance with mucosal injury and glottis
dysfunction associated with prolonged intubation further aggra-
vates the risk of VAP with re-intubation [2]. Daily interruption of
sedative infusions in critically ill patients receiving mechanical
ventilation decreases the duration of mechanical ventilation and
reduces the length of intensive care unit (ICU) stay. Consequently,
this practice can be considered worthy for reducing VAP risk and
its occurrence [3,4].sidered a microbiological emergency because of its impact on disease
associated morbidity and mortality and antibiotic management, so
rapid diagnostic information is clearly more beneficial to patients
than more complete but delayed information. Multiplex-PCR is a
universal technique making it possible to identify more than one
micro-organism, from single patient’ specimen [3,4].
The aim of this study was to identify the causative bacterial
pathogens of VAP by both conventional microbiological cultures
and multiplex reverse transcriptase reaction (m-PCR) methods
with assessment of turnaround time for both diagnostic modalities
together with their diagnostic accuracy.
2. Patients and methods
2.1. Study setting
This study was conducted in pediatric intensive care unit (PICU)
of Ain Shams University Hospital, which is a multidisciplinary
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ing time of the study.
2.2. Patients’ data acquisition
Demographic variables such as gender, age, underlying disease
together with the patients’ clinical data, and degree of critical ill-
ness by Pediatric Logistic Organ Dysfunction (PELOD) score [5],
length of PICU stay, duration of mechanical ventilation, and antibi-
otic regimen were collected from patients’ records after getting the
care ‘caregivers’ consent and the approval of ethical committee of
Ain Shams University. The work has been carried out in accordance
with the Code of the World Medical Association (Declaration of
Helsinki) for experiments in humans. Data collection began within
24 h from the time of admission to the PICU.
2.3. Patients’ enrollment
All admitted patients were observed daily for the diagnosis of
VAP. The method of establishing the diagnosis of VAP remains con-
troversial and no method has emerged as the gold standard. For
these reasons, clinical guidelines are available to aid in decision
making about acquisition of ventilator-associated pneumonia
[5,6]. We used the Clinical Pulmonary Infection Score (CPIS) to help
quantify clinical findings and represents a ‘‘weighted approach” to
the clinical diagnosis of VAP. This scoring system includes both
clinical and radiological factors that increase the likelihood of the
presence of VAP. Point values are assigned to each criteria and a
sum is calculated. Traditionally, a threshold score of more than
six has been used to diagnose VAP (Table 1) [5,6].
2.4. Microbiological assessment
2.4.1. Clinical specimens
Endotracheal aspirate (ETA) was screened from enrolled
patients. These specimens were tested against important and com-
mon bacterial pathogens by both bacterial culture and multiplex
Polymerase Chain Reaction (m-PCR).
2.4.2. Bacterial cultures
Specimens were obtained and sent to the laboratory within one
hour of collection. They were decontaminated and centrifuged
before inoculation. Inoculation was on Blood agar and Chocolate
agar for blood specimens and further on McConkey agar for ETA.
Specimens were incubated for one week and observed for colonies
every day in ETA and every 48 h in blood specimens. Colonies were
identified by gram stain and biochemical profile. Infection was
defined by semi-quantitative count of more than 105 CFU/ml.
Antibiotic sensitivity test was done for positive isolates using discTable 1
Modified Clinical Pulmonary Infection Score.
Measurement Points
0 1
Temperature (C) 36.5–38.4 38.5–38.9
Peripheral white blood cell count 4000–11,000 <4000 or >11
add 1 extra p
Tracheal secretions None Nonpurulent
Chest radiograph No infiltrate Diffuse or pa
Progression of infiltrate from
prior radiographs
None
Culture of endotracheal tube suction No growth/light growth Heavy growt
on gram stai
Oxygenation (Pao2/fraction
of inspired oxygen [Fio2])
>240 or acute respiratory
distress syndrome
Adapted from Alicia et al. [5] and Swoboda et al. [6].diffusion method according to National Committee for clinical Lab-
oratory standards (NCCLS) [7]. Isolated bacterial agents are Strepto-
coccus pneumoniae, Methicillin-resistant Staphylococcus (MRSA),
Klebsiella pneumoniae, Mycoplasma pneumoniae, Chlamydia pneu-
moniae, Pseudomonas aerogenosa, Legionella pneumophilia and
Acinetobacter.
2.4.3. Multiplex PCR
Collected specimens were assessed for seven bacterial agents;
that are considered serious causative pathogens for VAP world-
wide. These organisms are sharing some physical properties during
their processing for PCR (Acinetobacter was not involved in the
panel because it has different incubation temperature than the
selected primers for the other 7 organisms). DNA extraction: DNA
was extracted from the samples using MagNA pure Compact
Nucleic Acid Isolation Kit I (Cat. No. 03730964001); supplied by
(Roche, Germany). Amplification by PCR: This was done by Light
Cycler-DNA Amplification Kit SYBR Green I (Cat. No. 2015137).
The kit used Light Cycler 2.0 System (Roche, Germany). Primers:
Primers were non-labeled forward primers and biotin-labeled
reverse primers with horseradish peroxidase – labeled probes. Pri-
mers for Mycoplasma pneumoniae, Chlamydia pneumoniae, Legio-
nella pneumophilia, Staphylococcus aureus, and Streptococcus
pneumoniae were selected according to Kumar et al. [7]. Primers
for Klebsiella pneumoniae were made according to Kurupati et al.
[8]. Primers for Pseudomonas aerogenosa were chosen according
to Qin et al. [9].
2.4.4. Turnaround time (TAT)
We calculated brain to brain TAT (Total TAT) as outlined by
Lundberg including the total testing cycle as a series of nine steps:
ordering, collection, identification, transportation, preparation,
analysis, reporting, interpretation and taking a decision by the
ordering physician. We used the term Laboratory TAT as the time
elapsed from physician request of the laboratory test till a report is
available by the laboratory [10].
2.5. Statistical analysis
Analysis of data was done by IBM computer using SPSS 12-USA.
Description of quantitative variables is expressed as mean and
standard deviation (SD). Description of qualitative variables is
expressed as number and percentage. The Wilcoxon’s signed-
rank test compared the difference between culture and PCR in dif-
ferent study specimens. There is no gold standard for the diagnosis
of VAP in pediatric patients; therefore, we used a Clinical Pul-
monary Infection Score of NNIS (National Nosocomial Infections
Surveillance) age-specific guidelines. Sensitivity and Specificity of





tchy infiltrate Localized infiltrate
Progression (acute respiratory distress
syndrome or congestive heart failure thought unlikely)
h (some bacteria
n: add 1 extra point
240 and no acute respiratory
distress syndrome
Table 3
Turnaround time and cost of both endotracheal aspirate cultures and multiplex PCR.
ETA Cultures Multiplex PCR P
Mean Turnaround time; hours (Range)
Laboratory TAT for positive test 87 (48:186) 14 (9:24) <0.0001
Laboratory TAT for negative test 147 (96:220) 14 (9:24) <0.0001
Total TAT for positive test 107 (60:180) 20 (15:40) <0.0001
Total TAT for negative test 190 (108:230) 20 (15:40) <0.0001
Total Cost (Egyptian pounds) 9600 13,800 <0.0001
Table 4
Summary of m-PCR and microbiological culture results in endotracheal aspirate
(ETA).
Variable ETA (n = 46)
Culture m-PCR p
Positive cases, n (%) 35 (76%) 11 (24%) <0.001
Streptococcus pneumoniae 4 (8.6%) – <0.16
Methicillin-resistant
Staphylococcus (MRSA)
12 (26%) – <0.01
Klebsiella pneumoniae 18 (39%) 9 (19.5%) 0.03
Mycoplasma pneumoniae 11 (24%) – <0.01
Chlamydia pneumoniae 2 (4%) – 0.3
Pseudomonas aerogenosa – 4 (8.6%) 0.16
Legionella pneumophilia – –
Acinetobacter# – 12 (28%) –
Acinetobacter# & MRSA – – –
Klebsiella pneumoniae &
Pseudomonas aerogenosa
– 1 (2%) –
Acinetobacter# is not involved in the m-PCR panel.
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of VAP) [6].
Sensitivity of culture or m-PCR represents the proportion of
patients with VAP who test positive. Specificity is the proportion
of patients without HAP who test negative. Predictive value of a
positive test (PPV) is the proportion of patients with positive tests
who have disease. Predictive value of a negative test (NPV) is the
proportion of patients with negative tests who do not have disease.
Laboratory turnaround time and total turnaround times were cal-
culated in hours and were compared two-sample t-test for Inde-
pendent samples.
3. Results
3.1. Patients’ cohort characteristics
Ninety-six patients were admitted to the PICU during the study
period with mean age 21 ± 18.7 months, and males represented
53% of them. Their median PELOD score was 24 with predicted
mortality rate of 34%. Almost half of admitted cases were admitted
due to neurological emergency (coma and acute flaccid paralysis).
Recorded frequency of VAP was 48% according to CIPS score during
the study period with a rate of 23 per 1000 patients’ days. Twenty-
one patients developed early VAP while twenty-five patients had
late onset VAP. Forty-four percent of patients with VAP were less
than 12 months, and 84.5% of them were males. The distribution
of the primary cause of PICU admission didn’t differ significantly
between patients who acquired VAP and those who didn’t
(Table 2).
3.2. Clinical outcomes of Ventilator-associated pneumonia
Length of PICU stay was doubled in patients who acquired VAP
compared to patients without VAP (p < 0.05). Duration of mechan-
ical ventilation was significantly longer in patients with VAP
(p < 0.01). VAP lead to 10% increment in the actual mortality rate
above the predicted rate for the affected patients with significant
higher mortality than patients without VAP (Table 2).
3.3. Turnaround times for bacterial culture and multiplex PCR
Laboratory turnaround times for mPCR constitutes nearly one-
sixth of positive culture (p < 0.0001) and one-tenth for mPCR com-
pared to negative culture (p < 0.0001). A highly significant similarTable 2




Mean age ± SD, months 21 ± 18.7
Male sex, n (%) 51 (53%)
Median PELOD* Score (interquartile range) 24 (939)
Admission Diagnosis, n (%)
Pulmonary Diseases 12 (12.5%)
Cardiac Diseases 13 (14%)
Neurologic Diseases 46 (48%)
Acute Gastrointestinal Infections 11 (11%)
Postoperative 16 (16%)
Outcome
Length of PICU* Stay, Days; mean ± SD 34 ± 47
Length of MV*, Days; mean ± SD 30 ± 35
Predicted Mortality rate%, (range) 34% (1–99)
Actual Mortality, n (%) 31 (32%)
Rate of VAP, n/1000 patient days –
PELOD* Pediatric Logistic Organ Dysfunction; PICU* Pediatric intensive care; MV*, Mechadiscrepancy of total TAT were found between mPCR and culture.
On the other hand, the total cost of the molecular diagnosis by
mPCR was significantly higher than microbiological culture
(Table 3).
3.4. Etiologic diagnosis of VAP by multiplex-PCR and microbiological
culture
In our study, multiplex-PCR had a better diagnostic yield for
VAP than bacterial culture (sensitivity 76%, specificity 97%, PPV
90%, NPV 93% vs. 24%, 92%, 55%, 79% respectively for culture).
Acinetobacter was the most frequent organism isolated by
culture followed by Klebsiella pneumoniae and Pseudomonas aeroge-





22.5 ± 19.8 23.6 ± 18 0.61
39 (84.5%) 12 (24%) <0.01
25 (10–42) 23 (939) 0.71
5 (12%) 7 (13%) 0.96
5 (12%) 8 (15%) 0.69
23 (52%) 23 (46%) 0.61
6 (12%) 5 (10%) 0.69
7 (12%) 9 (17%) 0.67
44 ± 45 22 ± 34 <0.05
39 ± 43 22 ± 28 <0.01
34% (1–90) 36% (2–98) –
20 (44%) 11 (23%) 0.04
23 – –
nical ventilation; VAP*, Ventilator-associated pneumonia.
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Mycoplasma pneumoniae. Polymicrobial Pneumonia was diagnosed
in two patients, where a combined growth of MRSA and
Acinetobacter was present in one patient and combined growth of
Pseudomonas aerogenosa and Klebsiella pneumonia in another
patient.
4. Discussion
Both developed and resource-poor countries are faced with the
burden of health care-associated infections. Ventilator-associated
pneumonia (VAP) is a complication in patients on mechanical ven-
tilation [11]. The frequency of registered VAP in our PICU during
this study reached 44% of patients on mechanical ventilation with
a rate of 23 per 1000 patients admission days with associated mor-
tality rate of 44% with predominance of gram-negative pathogens;
Klebsiella pneumoniae was diagnosed in 41%, Acinetobacter in 28%
with MRSA in 24%. For a resource-limited country with inappropri-
ate infection control measures together with relatively high occu-
pancy rate and high patients nurse ratio; we unfortunately could
encounter this high prevalence and so forth the mortality burden.
Patra et al. reported that VAP constituted 76% of patients with hos-
pital acquired pneumonia and represented the most frequent noso-
comial infection in intensive care units (80%) with an overall
mortality reaching 60%; Pseudomonas contributing to 57.1% of
deaths followed by Klebsiella, E. coli and Acinetobacter [1,12]. The
increasing incidence of infections caused by antibiotic-resistant
pathogens contributes to the emerging seriousness of these infec-
tions with expected higher mortality rate [13].
In our study; the mean length of stay was doubled following
VAP together with 50% increment in the mean duration of mechan-
ical ventilation days. In another study, VAP lengthens the hospital
stay by 7–9 days and is associated with a higher cost of medical
care [13]. Fifty-two percent of enrolled patients with VAP in our
study were admitted primarily to the PICU due to neurological
emergencies (e.g. acute flaccid paralysis with rapid progression
to involve respiratory muscles, status epileptics and coma). This
group of patients had major risks of aspirations [14,15].
The microbial etiology of VAP varies according to patients’ med-
ical condition, the duration of ICU stay, the antibiotic policy and
the prior exposure to antimicrobials. All these factors significantly
influence the distribution patterns of etiologic agents from one ICU
to another [15,16]. The most frequent organisms detected in our
study were Klebsiella pneumoniae (40%), Acinetobacter (28%) and
followed by Mycoplasma pneumoniae (24%) and MRSA (24%), while
the least common isolates were Streptococcus pneumoniae (8%) and
Chlamydia pneumoniae (4%).
Acinetobacter baumannii is now recognized to be capable of
causing life-threatening infections including pneumonia [17]. This
appears to be due to their ability to survive on health-care workers’
hands and environmental surfaces and their intrinsic resistance to
many common antibiotics, rather than any intrinsic virulence fac-
tors [3,17]. Antibiotic therapy and critical illness can suppress the
normal bacterial flora and lead to an overgrowth of Enterobacteri-
aceae like Klebsiella pneumoniae in the respiratory tracts. The most
concerning is the acquisition of extended-spectrum b-lactamases
that render the bacteria resistant to penicillin and cephalosporin
antibiotics [18]. Extended spectrum b-lactamase (ESBL) producing
Klebsiella pneumoniae may cause serious nosocomial infections
especially in critically ill patients. Numerous outbreaks have been
described with ICU-acquired ESBL-producing Klebsiella pneumoniae
[17].
MRSA was detected as a causative agent for HAP in 24% of cases
in our study bym-PCR. Staphylococcus aureus (both Methicillin sen-
sitive and resistant strains), constitutes the most frequently iso-
lated pathogen in the ICU. The incidence of MRSA as a cause ofVAP was 12–15%, but increased to approximately 30% in patients
with prolonged mechanical ventilation and prior antibiotic therapy
[19,20]. Mycoplasma pneumoniae was not detected by bacteriolog-
ical cultures but was detected in 24% of patients and diagnosed
only by m-PCR. Altogether with VAP task forces, the emergence
of resistance is a concern for intensive care specialists worldwide
thus it is imperative for investigators from different countries
and regions to exchange precise and updated epidemiological data
on the encountered HAP and VAP.
The use of PCR leads to an increase in diagnostic sensitivity,
especially in micro-organisms that can’t be easily cultured and in
case of a low burden of micro-organisms with previous antibiotic
therapy [21]. In our study, m-PCR optimized the diagnosis and
management of VAP over bacterial culture. Both the laboratory
and total turnaround times were remarkably shorter compared
to microbial culture, hence substantial reduction of unnecessary
antibiotic prescriptions seemed possible. This is in agreement with
Strålin et al. [22], who recommended multiplex PCR to be a useful
etiological diagnostic tool in lower respiratory tract infection
patients, particularly in those treated with antibiotics. Inspite of
the well-known high costs of real time PCR, multiplex reverse tran-
scriptase PCR still had a lower cost and the advantage of the rapid
and simultaneous detection rate of many bacterial pathogens in
upper and lower respiratory tract infections significantly compared
to that of the conventional culture method. The same was sug-
gested early by Hendolin et al. [23,24] where multiplex PCR
method improved the diagnosis and management of hospital and
community-acquired pneumonia.
5. Conclusion
Ventilator associated pneumonia negatively impacts clinical
outcome and resource consumption in studied critically ill pedi-
atric patients by prolonging the length of mechanical ventilation
and ICU stay and increase associated hospital mortality rate. Mul-
tiplex PCR optimized the emergency diagnosis of VAP over bacte-
rial culture, especially in micro-organisms that can’t be easily
cultured. It is considered a rapid, reliable and efficient diagnostic
service that has been delivered at a relatively accepted cost.
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